"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 5 | 0 | 5 |
| 2003 | 1 | 0 | 1 |
| 2005 | 5 | 0 | 5 |
| 2006 | 4 | 0 | 4 |
| 2007 | 3 | 0 | 3 |
| 2008 | 9 | 0 | 9 |
| 2009 | 6 | 0 | 6 |
| 2010 | 14 | 2 | 16 |
| 2011 | 21 | 0 | 21 |
| 2012 | 29 | 2 | 31 |
| 2013 | 19 | 1 | 20 |
| 2014 | 13 | 3 | 16 |
| 2015 | 25 | 2 | 27 |
| 2016 | 14 | 0 | 14 |
| 2017 | 16 | 1 | 17 |
| 2018 | 23 | 0 | 23 |
| 2019 | 21 | 1 | 22 |
| 2020 | 23 | 2 | 25 |
| 2021 | 20 | 0 | 20 |
| 2022 | 20 | 0 | 20 |
| 2023 | 6 | 0 | 6 |
| 2024 | 10 | 0 | 10 |
| 2025 | 12 | 0 | 12 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth. Mol Cancer Ther. 2026 Feb 04; 25(2):257-271.
-
Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma. Nat Commun. 2025 Dec 31; 17(1):1343.
-
Impact of electronic patient-reported outcomes (ePRO) presentation in pancreatic cancer tumor board discussions on cancer outcomes: the INSPIRE intervention. BMC Cancer. 2025 Dec 30; 26(1):182.
-
A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection. ACS Nano. 2025 Dec 23; 19(50):42056-42065.
-
A novel D-peptide modulates DCLK1 gelsolin interactions, reducing PDAC tumor growth. Sci Rep. 2025 Oct 14; 15(1):35811.
-
The Level of a Short Form of Multidrug Resistance-Associated Protein 1 Is Elevated in Plasma Small Extracellular Vesicles Derived From Patients With Pancreatic Ductal Adenocarcinoma. FASEB J. 2025 Jul 31; 39(14):e70849.
-
Extracorporeal blood filtration leading to tumor growth arrest and reduced analgesic requirements in Stage IV poorly differentiated pancreatic adenocarcinoma: A case report. Oncotarget. 2025 Jul 23; 16:582-586.
-
Advances in Imaging of Pancreatic Adenocarcinoma. Surg Oncol Clin N Am. 2026 Jan; 35(1):33-54.
-
Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy. Clin Cancer Res. 2025 May 15; 31(10):1821-1823.
-
Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma. J Clin Invest. 2025 Apr 01; 135(7).